Efficacy and Safety of NVX-CoV2705

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

6,500

Participants

Timeline

Start Date

November 10, 2025

Primary Completion Date

January 9, 2026

Study Completion Date

July 9, 2026

Conditions

COVID-19Sars-CoV-2 Infection

Interventions

BIOLOGICAL

NVX-CoV2705

NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant

BIOLOGICAL

Placebo

Placebo (normal saline) in a 0.5 mL injection volume.